| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Enhancer of zeste homologue 2 (EZH2) is overexpressed in many types of cancer and associated with poor prognosis. However, the underlying mechanism of EZH2 overexpression is not fully understood. Using an EZH2 promoter inhibition assay with an siRNA library targeting known human kinases in colorectal cancer cell lines, we identified a novel role for the IKBKE－NF-κB pathway in upregulating EZH2 expression. IKKe a kinase, was observed to be highly expressed in colorectal cancer tissue. Further validation revealed that inhibiting IKBKE caused a significant reduction in EZH2 expression. These data suggest that the IKKe;－NF-κB pathway may play an important role in regulation of EZH2 expression in colorectal cancer.
|
